Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Review Article Volume 3 Issue 3

Th17 Inducing Vaccine Against Tuberculosis May Cause Autoimmunity and Inflammation Mediated Adverse Effects

Om Parkash*

Former Scientist-F (Immunology), National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Taj Ganj, Agra, Uttar Pradesh, India

*Corresponding Author: Om Parkash, Former Scientist-F (Immunology), National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Taj Ganj, Agra, Uttar Pradesh, India.

Received: February 13, 2020; Published: March 03, 2020



  Tuberculosis (TB) is a big global health problem and an effective vaccine for control of this disease is urgently required. In the recent past, a concept has emerged wherein it has been shown that a CD4+ Th1 cell stimulating anti TB vaccine can be more effective if it has CD4+ Th17 cell stimulating property as well. With such an anti TB vaccine, the Th1 mediated immunity can further become stronger due to supportive effect of immune response induced by Th17 cell. Since Th1 and Th17 cells are pro inflammatory in nature, a TB vaccine capable of stimulating both of these cells may result in generation of a cumulative stronger pro inflammatory immune response. This raises an apprehension that such an increased immune response may cause adverse effects in the form of autoimmunity and inflammation in the vulnerable vaccinated subjects. Therefore, extensive studies to understand the spectrum and magnitude of occurrence of such diseases must be carried out with Th1 and Th17 inducing anti TB vaccine (s). This might help in understanding their risk/ benefit ratio while employing such Th1-Th17 inducing vaccines for clinical practice.

Keywords: Vaccine; Tuberculosis; Th17; Autoimmunity; Inflammation



  1. Stop TB Partnership UNOPS. “The Paradigm Shift 2018-2022: Global Plan to End TB”. Geneva: Stop TB Partnership UNOPS (2019).
  2. Ottenhoff TH and Kaufmann SH. “Vaccines against tuberculosis: where are we and where do we need to go?”. PLOS Pathogens 8 (2012): e1002607.
  3. Atmakuri K., et al. “Meeting report: 5th Global Forum on TB Vaccines, 20-23 February 2018, New Delhi India”. Tuberculosis (Edinb) 113 (2018): 55-64.
  4. Schrager LK., et al. “The status of tuberculosis vaccine development”. The Lancet Infectious Diseases (2020). 
  5. Parkash O. “T Regulatory Cells and BCG as a Vaccine against Tuberculosis: An Overview”. World Journal of Vaccines 5 (2015): 96-105.
  6. Cooper AM. “Cell-mediated immune responses in tuberculosis”. Annual Review of Immunology 27 (2009): 393-422. 
  7. Khader SA and Gopal R. “IL-17 in protective immunity to intracellular pathogens”. Virulence 1 (2010): 423-427.
  8. Rakshit S., et al. “Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL 10+ Th17 CD4 T-cells differentiate latent from active tuberculosis”. Scientific Reports 17 (2017): 11948.
  9. Desel C., et al. “Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses”. The Journal of Infectious Diseases 204 (2011): 1573-1584. 
  10. De Cassan SC., et al. “Investigating the induction of vaccine- induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG- immunized adults vaccinated with a new tuberculosis vaccine, MVA85A”. Clinical and Vaccine Immunology 17 (2010): 1066-1073. 
  11. Day CL., et al. “Induction and regulation of T cell immunity by the novel TB vaccine M72/AS01 in South African adults”. American Journal of Respiratory and Critical Care Medicine 188 (2013): 492-502.
  12. Kumar P., et al. “Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a TLR-dependent manner”. Journal of Leukocyte Biology 97 (2015): 511-520.
  13. Back YW., et al. “Cell wall skeleton of Mycobacterium bovis BCG enhances the vaccine potential of antigen 85B against tuberculosis by inducing Th1 and Th17 responses”. PLoS One 14 (2019): e0213536.
  14. Sakaguchi S., et al. “Regulatory T cells and immune tolerance”. Cell 133 (2008): 775-787.
  15. Chen Z and O’Shea JJ. “Th17 cells: a new fate for differentiating helper T cells”. Immunologic Research 41 (2008): 87-102.
  16. Eisenstein EM and Williams CB. “The T(reg)/Th17 cell balance: a new paradigm for autoimmunity”. Pediatric Research 65 (2009): 26R-31R.
  17. Maddur MS., et al. “Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies”. The American Journal of Pathology 181 (2012): 8-18.
  18. Silfvast-Kaiser A., et al. “Anti-IL17 therapies for psoriasis”. 19 (2019): 45-54.
  19. Sallusto F and Lanzavecchia A. “Human Th17 cells in infection and autoimmunity”. Microbes and Infection 11 (2009): 620-624.


Citation: Om Parkash. “Th17 Inducing Vaccine Against Tuberculosis May Cause Autoimmunity and Inflammation Mediated Adverse Effects". Acta Scientific Microbiology 3.4 (2020): 08-11.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US